Are shares in GlaxoSmithKline plc now in bargain territory?

Paul Summers casts his eyes over today’s results from pharmaceutical giant GlaxoSmithKline plc (LON:GSK).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in FTSE 100 pharmaceutical giant GlaxoSmithKline (LSE: GSK) were in the red this afternoon. That was despite the company reporting a 21% rise in sales (in sterling terms) over the fourth quarter and “continued momentum” in 2016 as a whole. Does this present a buying opportunity for private investors? 

Return to form?

Over the full year to the end of December, group sales climbed 6% to £27.9bn, with all three of its businesses registering growth. Broken down, Vaccines was the best performing segment, with sales rising 14% to £4.6bn compared with the previous year. Pharmaceutical sales — which still contribute the bulk of the company’s profits — rose 3% to £16.2bn, while its Consumer Healthcare business also recorded growth of 9% to £7.2bn.

Perhaps most positively, new product sales at the company more than doubled to £4.5bn in 2017 with its HIV treatments, respiratory medicines and meningitis vaccines performing strongly. 

Although total earnings per share for the year came in significantly lower at 18.8p, this was largely due to the prior year’s results including the £9.2bn profit Glaxo made after selling its Oncology assets to fellow pharmaceutical giant Novartis in 2015.

Commenting on results for the final time, outgoing CEO Sir Andrew Witty said that the next two years would be “significant” for the company’s pipeline and mark the beginning of “another intense period of R&D activity“.

Bargain buy?

Despite today’s fairly positive news, shares in GlaxoSmithKline trade on just 14 times earnings for 2017. Factor-in the chunky (if stagnant) 5% yield and the investment case starts to look interesting.

Whether investors should consider buying a slice of the company will probably rest, however, on how kind they believe 2017 will be to it. After benefiting from sterling’s recent weakness, Glaxo will be hoping that exchange rates remain around their current level for the rest of the year. If not, its share price may come under renewed pressure.

It has also indicated that performance will depend on whether a generic version of its blockbusting lung drug, Advair, is introduced to the US market. If one doesn’t appear, core earnings per share will come in somewhere between up 5% and 7%. Should its fears be realised, earnings will be either be flat or slightly lower.

Jam tomorrow?

Although its hard to say whether shares in Glaxo are a bargain at the current time, they do look a better play on the pharmaceutical sector when compared to those of FTSE 100 peer, Astrazeneca (LSE: AZN).

Despite posting stronger-than-expected Q4 earnings last Thursday. The £56bn cap provided a gloomy outlook for 2017 after highlighting that sales — particularly those relating to its blockbuster drug, Crestor — were continuing to come under pressure from generic competitors. In contrast to GlaxoSmithKline, the company went so far as to predict a “low-to-mid single-digit” decline in total revenues and “a low-to-mid-teens percentage decline” in core EPS.  

Even though a P/E of 15 for 2017 (reducing to 14 next year) doesn’t appear overly expensive, I continue to be concerned by the company’s ‘jam tomorrow’ message. Talk of reaching the end of its “patent-expiry period” and the unveiling of “several life-changing medicines for cancer, respiratory and metabolic diseases” over the course of this year is all very well. But I still need to be convinced that the Astrazeneca’s return to long-term growth is as close as management claims.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Paul Summers has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »